Sugi Predict

Sugi Predict / Compounds / SCHEMBL2373369

SCHEMBL2373369

SCHEMBL2373369

CC(C)Oc1cc([N+](=O)[O-])ccc1Br

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 4/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ HTT P42858 3/20 0.47
▸ TDP1 Q9NUW8 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ TSHR P16473 2/20 0.42
▸ PTPRC P08575 3/20 0.41
▸ S100A4 P26447 2/20 0.41
▸ KMT2A Q03164 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ PDK1 Q15118 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ BCHE P06276 1/20 0.40
▸ ACHE P22303 1/20 0.40
▸ CES1 P23141 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8113158 0.87 CYP19A1 (0.54) CYP19A1SMN1; SMN2LMNAHTTTDP1
SCHEMBL11835883 0.84 CYP19A1 (0.61) CYP19A1SMN1; SMN2LMNAHTTTDP1
SCHEMBL4362884 0.83 MEN1 (0.45) CYP19A1SMN1; SMN2LMNAHTTTDP1
SCHEMBL30135030 0.83 MEN1 (0.45) CYP19A1SMN1; SMN2LMNAHTTTDP1
SCHEMBL8321749 0.83 CYP19A1 (0.50) CYP19A1SMN1; SMN2LMNAHTTTDP1
SCHEMBL9699062 0.81 CYP19A1 (0.58) CYP19A1SMN1; SMN2LMNAHTTTDP1
SCHEMBL3295088 0.81 HTT (0.67) CYP19A1SMN1; SMN2LMNAHTTTDP1
SCHEMBL282839 0.81 HTT (0.66) CYP19A1SMN1; SMN2LMNAHTTTDP1
SCHEMBL31555017 0.80 HTT (0.50) SMN1; SMN2LMNAHTTTDP1ALDH1A1
SCHEMBL2910419 0.80 CYP19A1 (0.57) CYP19A1SMN1; SMN2LMNAHTTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070287-A IRAK 4-targeted degradation agent compound and application thereof 江苏先声药业有限公司 2026-05-19 — — CN disclosed
US-20250214948-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2025-07-03 — — US disclosed
WO-2025077891-A1 DEGRADATION AGENT COMPOUND TARGETING IRAK4, AND USE THEREOF 江苏先声药业有限公司 2025-04-17 — — WO disclosed
CN-111819172-B Triazine derivatives for the treatment of neurotrophin related diseases 阿泽克制药公司 2024-02-06 — — CN disclosed
EP-3759088-B1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2023-01-25 — — EP disclosed
US-20220306589-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2022-09-29 — — US disclosed
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins AlzeCure Pharma AB (SE) 2022-06-07 — — US disclosed
EP-3759088-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS Alzecure Pharma AB (SE) 2021-01-06 — — EP disclosed
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2020-12-24 — — US disclosed
CN-111819172-A Triazine derivatives for the treatment of neurotrophin-related disorders 阿泽克制药公司 2020-10-23 — — CN disclosed
WO-2019162702-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2019-08-29 — — WO disclosed
WO-2018106646-A1 AMINOTRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2018-06-14 — — WO disclosed
WO-2018106646-A1 AMINOTRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2018-06-14 — — WO disclosed
WO-2011119693-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE LLC (US) 2011-09-29 — — WO disclosed
WO-2011119704-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE LLC (US) 2011-09-29 — — WO disclosed
US-6706754-B2 ANTIPROTOZOA AGENTS, PARASITICIDES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY 2004-03-16 — — US disclosed
US-20020156098-A1 Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis ARMY, UNITED STATES 2002-10-24 — — US disclosed
WO-2002036588-A2 REVERSED AMIDINES AND METHODS OF USING FOR TREATING, PREVENTING, OR INHIBITING LEISHMANIASIS U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) 2002-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306589-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF CYP19A1 1999/4885SMN1; SMN2 649/4885LMNA 1137/4885
US-20250214948-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF CYP19A1 1999/4885SMN1; SMN2 649/4885LMNA 1137/4885
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins NTRK2, BDNF, NGF CYP19A1 1532/4885SMN1; SMN2 619/4885LMNA 1198/4885
US-20020156098-A1 Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis ARG1, NAT1, CTSA CYP19A1 3010/4885SMN1; SMN2 3757/4885LMNA 515/4885
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF CYP19A1 1532/4885SMN1; SMN2 619/4885LMNA 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.